BIO launches V2, can the new Launchpad restart the Desci craze?

After experiencing a trough in price, DeSci track leader BIO recently launched a V2 version, introducing new mechanisms such as Launchpad and staking points, and the market value quickly recovered, rekindling the market's attention and expectations for decentralized science. Can DeSci solve the "broken window effect" of research funding? (Background supplement: Changpeng Zhao CZ: donated $10 million BNB to Vitalik a few months ago to fund the DeSci project) The leading $BIO of the DeSci track, once regarded as a pioneer in "scientific research and crypto convergence", has been under pressure since its launch in January this year - although top investors including V God and CZ stand behind it, they still have not escaped the dual impact of the market and liquidity, and the market value has shrunk by 95% from the opening high. For a while, it became the focus of community dissatisfaction and doubts, and also made the track that once ran out of the myth of hundreds of millions of market capitalizations such as $RIF and $URO fall into a trough. However, with the recent official launch of the BIO Protocol V2 version, the introduction of new mechanisms such as Launchpad and staking points, the total amount of staked exceeded 100 million BIOs within a week of launch, and the market value quickly doubled to exceed 200 million US dollars, once again igniting the market's attention and imagination of the DeSci track. Why did the $BIO of the luxury lineup fall off the altar? The listing story of BIO was originally the highlight of the DeSci track: Binance, OKX, Kraken and other first-tier exchanges came into battle, TGE's first-day trading volume exceeded $2 billion, and FDV once stood at $250 million, becoming the most sensational scientific crypto asset issuance in early 2025. However, behind the excitement lies the foreshadowing of the price drop. However, the heat of this feast did not last long. BIO is issued in an auction model, with an initial circulation ratio higher than most Singapore coins, and then superimposed on the valuation that is pushed up by listing, making it appear inflated in price in the absence of immediate utility. The initial market orders were driven more by narrative and emotion than by practical value. While key features such as Launchpad, staking system, and BioXP points remained on the plan, investors quickly discovered that their tokens did not bring real returns on participation or governance rights in the short term. The gap between valuation and usage scenarios becomes the first force for prices to slide from high places. The downside of BIO is also closely related to the issue of rhythm. The core functionality failed to go live synchronously on the same day of TGE, and the market's confidence began to drain during the waiting window. In terms of ecological expansion, Molecule Catalyst's arrangement to operate Launchpad independently distracts funds and attention, weakening the cohesion of the main platform. In addition, the macro market has entered a stage of cooling risk appetite, and funds are quickly withdrawn from projects with high FDV and no immediate cash flow. Lacking continuous news support and product landing rhythm, BIO has gradually fallen into the trough of thin transaction and price bottom from the star project at the beginning of the year. The re-emergence of BIO Protocol to create a scientific research acceleration experimental field In the first half of 2025, BIO Protocol has gone through a period of ups and downs - from the peak of the narrative at the beginning of the year all the way to the price trough, but the pace has not slowed down by half a minute. It has not only delivered the most dazzling market results on the DeSci track, but also pushed several biological drugs to the clinical gate, allowing "on-chain scientific research" to smell the breath of real medical verification for the first time. The price drawdown did not repel the team's ambitions, but in exchange for more construction actions: in May, BIO delayed the unlocking of teams and consultants through community governance, sending a signal to the market that "we are here to fight for a long time". The progress of scientific research is also remarkable - VitaRNA and VitaFAST both started clinical trials in the UAE, and it took only 11 months from concept to enrollment, compared with 4–6 years for traditional models; Fourteen compounds predicted by AI with a success rate of more than 85% are waiting for Q3 efficacy readouts. At the same time, five new BioDAOs, including QBIO, Long Covid Labs, Curetopia, SpineDAO, and MycoDAO, were established one after another, raising a total of $8.9 million during the year, injecting continuous fuel into this high-speed scientific research machine. V2: The Transition from DeSci 1.0 to DeSci 2.0 In addition, the BIO team officially launched Bio Protocol V2 in August, with the goal of bringing scientific research financing and execution into a "high-speed mode" to solve the pain points of high FDV debut, lack of real-time functions, and ecological decentralization in the DeSci 1.0 stage. The core of V2 lies in four engines: Low FDV fixed price debut: Referring to the successful path of Pump.fun and Virtuals, V2 reduced the initial valuation of the project to $205,000 FDV, 35% of the tokens were sold directly, and all the $BIO raised were injected into the liquidity pool, and there was depth and price momentum at the opening, allowing the community to be highly bound to the project. BioXP Points System: Quantifies stake, LP, on-chain interaction, social communication and other behaviors into points, and links them to DeSci Score, which are valid for 14 days and are used to allocate quotas for low-FDV projects, and high-engagement users will continue to enjoy priority opportunities. Staking > veBIO: Staking BIO not only earns points bonus, but also obtains governance voting rights; Other assets within the staking ecosystem have higher point yields, encouraging support for the entire network. Liquidity Engine: LPs are automatically generated after the initial launch, and a 1% handling fee is charged for each transaction in the secondary market (70% goes to the project treasury, 30% goes to the agreement), forming a positive cycle of "active trading - increase in scientific research funds - promotion of achievements - resurgence of market heat". Accelerating the implementation to welcome the new cycle of DeSci VitaRNA and VitaFAST are pushing DeSci from concept to reality. The two drugs will advance trials simultaneously in the UAE, Singapore and Switzerland, and are expected to be the first fully funded drugs by DeSci to enter the clinical stage within two years at a cost of less than $500,000. This not only breaks the cost barrier of traditional drug research and development for several years and tens of millions of dollars, but also sets a benchmark for on-chain scientific research. At the same time, BIO is carrying out pilot cooperation with Pfizer (Pfizer) to explore a compliant intellectual property tokenization (IPT) model, and build a new capital flow and value allocation mechanism for future drug research and development. Bio Protocol will launch a decentralized scientific research agent to automate key scientific research links such as drug screening, clinical operations, and capital scheduling. The upcoming BIO Copilot will become an on-chain research assistant for incarnate scientists, advancing scientific research to a programmable, scalable, and machine-driven stage, so that scientific research is no longer subject to human bottlenecks, but enters the intelligent track of high-frequency iteration. In addition, the flywheel of capital and market is also quietly starting. Launchpad 2.0 plans to launch 10–20 low-cap projects in the coming months, covering Agent, IPT, research tools, and more, raising an average of $70,000, Base...